Kamiya Toru, Ando Takafumi, Watanabe Osamu, Nakamura Masanao, Yamamura Takeshi, Miyahara Ryoji, Hirooka Yoshiki, Goto Hidemi
Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Department of Endoscopy, Nagoya University Hospital, Nagoya, Japan.
Nagoya J Med Sci. 2015 Feb;77(1-2):237-44.
Surveillance colonoscopy (SC) is considered important for the early detection and treatment of colorectal cancer (CRC) in patients with ulcerative colitis (UC). Here, we investigated whether current guidelines are appropriate in preventing UC patients from being diagnosed with CRC at an incurable stage. Among 1583 patients under treatment for UC, 27 patients were diagnosed with CRC. Of these, we excluded two patients who had not undergone colonoscopy before CRC diagnosis. We then divided the remaining patients into three groups based on colonoscopy interval (A, 1 year or less; B, between 1 and 2 years; and C, 2 years or longer). Fifteen patients had tubular adenocarcinomas, and 10 had other types (8 poorly differentiated adenocarcinomas, 1 mucinous adenocarcinoma, 1 endocrine cell carcinoma). Five (20%) of 25 patients developed CRC within 8 years after the onset of UC, of which one case was detected at stage IV. Six patients were classified into group A, 8 into group B, and 11 into group C. On distribution by histologic type, tubular adenocarcinomas were detected in stages 0 - II in 100% in group A, 100% in group B, and 57.1% in group C. In contrast, other types of carcinomas were detected in stage 0 - II in 100% in group A, 40% in group B, and 0% in group C. Current guideline recommendations for SC are not sufficient for the detection of early stage CRC in patients with UC. SC should be commenced earlier than recommended in the current guidelines and repeated annually.
监测性结肠镜检查(SC)对于溃疡性结肠炎(UC)患者结直肠癌(CRC)的早期检测和治疗具有重要意义。在此,我们调查了当前指南对于预防UC患者在癌症无法治愈阶段被诊断为CRC是否合适。在1583例接受UC治疗的患者中,27例被诊断为CRC。其中,我们排除了2例在CRC诊断前未接受结肠镜检查的患者。然后,我们根据结肠镜检查间隔时间将其余患者分为三组(A组,1年或更短;B组,1至2年;C组,2年或更长)。15例患有管状腺癌,10例患有其他类型(8例低分化腺癌、1例黏液腺癌、1例内分泌细胞癌)。25例患者中有5例(20%)在UC发病后8年内发生CRC,其中1例在IV期被检测到。6例患者被分类为A组,8例为B组,11例为C组。按组织学类型分布,A组0-II期管状腺癌的检出率为100%,B组为100%,C组为57.1%。相比之下,A组0-II期其他类型癌的检出率为100%,B组为40%,C组为0%。当前关于SC的指南建议不足以检测UC患者的早期CRC。SC应比当前指南建议的时间更早开始且每年重复进行。